Cargando…
Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia
BACKGROUND: Pandemic COVID-19 pneumonia due to SARS-2 is an important cause of morbidity and mortality. Emerging evidence links poor outcomes to an inflammatory cytokine storm. METHODS: We treated 89 hospitalized patients with COVID-19 pneumonia and heightened systemic inflammation (elevated serum C...
Autores principales: | Fomina, Daria S., Lysenko, Mar'yana A., Beloglazova, Irina P., Mutovina, Zinaida Yu., Poteshkina, Nataliya G., Samsonova, Inna V., Kruglova, Tat'yana S., Chernov, Anton A., Karaulov, Alexander V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Pathogens and Immunity
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556411/ https://www.ncbi.nlm.nih.gov/pubmed/33089038 http://dx.doi.org/10.20411/pai.v5i1.392 |
Ejemplares similares
-
Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study
por: Bryushkova, Ekaterina A., et al.
Publicado: (2022) -
Positive experience with TNF-α inhibitor in toxic epidermal necrolysis resistant to high-dose systemic corticosteroids
por: Nikitina, Ekaterina A., et al.
Publicado: (2023) -
Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
por: Fomina, Daria S., et al.
Publicado: (2023) -
Glycated hemoglobin level dynamics in COVID-19 survivors: 12 months follow-up study after discharge from hospital
por: Shestakova, Marina, et al.
Publicado: (2022) -
Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy
por: Lebedeva, Anna, et al.
Publicado: (2022)